"The commercial market has grown faster than the clinical evidence base," the paper read, and "the absence of adequate clinical evidence for use in humans is an alarming safety concern." Rita Jew, the ISMP president, told AFP "there's no new information that will make us feel comfortable" that the seven peptides should be authorizied for compounding
Understanding the difference between research and pharmaceutical grade peptides adds context to why testing matters
10.1159/000360490 180 QuinziiC
The combination of amylin and GLP-1 agonism may become a standard approach for obesity treatment, potentially displacing monotherapy as first-line pharmacological intervention
Xu Y, Xia Y, Liu Q, Jing X, Tang Q, Zhang J, et al